Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on August 21, 2019, 10:29:41 am
-
People with cirrhosis who were treated for hepatitis C virus (HCV) with Harvoni (ledipasvir/sofosbuvir) or Epclusa (sofosbuvir/velpatasvir) and who received intravenous (IV) proton pump inhibitors (PPIs) or histamine H2 agonists were cured of the virus at a high rate in a recent small study, the National AIDS Treatment Advocacy Project (NATAP) reports. This occurred despite the fact that such gastric acid drugs are known to lower the concentrations of the ledipasvir and velpatasvir components of the respective combination direct-acting antiviral (DAA) tablets.
Presenting their findings at the 20thInternational Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs in Noordwyk, the Netherlands, researchers at the University of Montreal conducted a study of 11 people with HCV from the MONTREAL-C study.
Read more...
https://www.hepmag.com/article/combo-gastric-acid-drugs-plus-harvoni-epclusa-tied-high-hep-c-cure-rate